Literature DB >> 33672962

Transglutaminase 2 as a Marker for Inflammation and Therapeutic Target in Sepsis.

Ting Su1,2, Xian-Yang Qin1, Yutaka Furutani1.   

Abstract

Sepsis results in lethal organ malfunction due to dysregulated host response to infection, which is a condition with increasing prevalence worldwide. Transglutaminase 2 (TG2) is a crosslinking enzyme that forms a covalent bond between lysine and glutamine. TG2 plays important roles in diverse cellular processes, including extracellular matrix stabilization, cytoskeletal function, cell motility, adhesion, signal transduction, apoptosis, and cell survival. We have shown that the co-culture of Candida albicans and hepatocytes activates and induces the translocation of TG2 into the nucleus. In addition, the expression and activation of TG2 in liver macrophages was dramatically induced in the lipopolysaccharide-injected and cecal ligation puncture-operated mouse models of sepsis. Based on these findings and recently published research, we have reviewed the current understanding of the relationship between TG2 and sepsis. Following the genetic and pharmacological inhibition of TG2, we also assessed the evidence regarding the use of TG2 as a potential marker and therapeutic target in inflammation and sepsis.

Entities:  

Keywords:  Elafin; antibacterial; antiviral; covalent crosslinking; inhibitor; sepsis; transglutaminase

Mesh:

Substances:

Year:  2021        PMID: 33672962      PMCID: PMC7918628          DOI: 10.3390/ijms22041897

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  112 in total

1.  Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2.

Authors:  Kyle B Johnson; Humphrey Petersen-Jones; Janice M Thompson; Kiyotaka Hitomi; Miho Itoh; Erik N T P Bakker; Gail V W Johnson; Gozde Colak; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

2.  Transglutaminase 2 gene ablation protects against renal ischemic injury by blocking constant NF-κB activation.

Authors:  Dae-Seok Kim; Bora Kim; Hongmin Tahk; Dong-Hyun Kim; Eu-Ree Ahn; Changsun Choi; Yoon Jeon; Seo Young Park; Ho Lee; Seung Hyun Oh; Soo-Youl Kim
Journal:  Biochem Biophys Res Commun       Date:  2010-11-19       Impact factor: 3.575

3.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome.

Authors:  Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

Review 4.  Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference.

Authors:  Dale M Needham; Judy Davidson; Henry Cohen; Ramona O Hopkins; Craig Weinert; Hannah Wunsch; Christine Zawistowski; Anita Bemis-Dougherty; Susan C Berney; O Joseph Bienvenu; Susan L Brady; Martin B Brodsky; Linda Denehy; Doug Elliott; Carl Flatley; Andrea L Harabin; Christina Jones; Deborah Louis; Wendy Meltzer; Sean R Muldoon; Jeffrey B Palmer; Christiane Perme; Marla Robinson; David M Schmidt; Elizabeth Scruth; Gayle R Spill; C Porter Storey; Marta Render; John Votto; Maurene A Harvey
Journal:  Crit Care Med       Date:  2012-02       Impact factor: 7.598

Review 5.  Apoptosis in sepsis.

Authors:  R Mahidhara; T R Billiar
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

Review 6.  Sepsis and septic shock.

Authors:  Richard S Hotchkiss; Lyle L Moldawer; Steven M Opal; Konrad Reinhart; Isaiah R Turnbull; Jean-Louis Vincent
Journal:  Nat Rev Dis Primers       Date:  2016-06-30       Impact factor: 52.329

Review 7.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

Review 8.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Nat Rev Immunol       Date:  2013-11-15       Impact factor: 53.106

Review 9.  Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders.

Authors:  Siiri E Iismaa; Bryony M Mearns; Laszlo Lorand; Robert M Graham
Journal:  Physiol Rev       Date:  2009-07       Impact factor: 37.312

Review 10.  Coeliac disease.

Authors:  Benjamin Lebwohl; David S Sanders; Peter H R Green
Journal:  Lancet       Date:  2017-07-28       Impact factor: 79.321

View more
  4 in total

1.  Inhibiting Transglutaminase 2 Mediates Kidney Fibrosis via Anti-Apoptosis.

Authors:  Jong-Joo Moon; Yejin Choi; Kyu-Hyeon Kim; Areum Seo; Soie Kwon; Yong-Chul Kim; Dong-Ki Kim; Yon-Su Kim; Seung-Hee Yang
Journal:  Biomedicines       Date:  2022-06-07

Review 2.  The Multifaceted Role of HSF1 in Pathophysiology: Focus on Its Interplay with TG2.

Authors:  Luca Occhigrossi; Manuela D'Eletto; Nickolai Barlev; Federica Rossin
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

3.  Erythrocyte transglutaminase-2 combats hypoxia and chronic kidney disease by promoting oxygen delivery and carnitine homeostasis.

Authors:  Ping Xu; Changhan Chen; Yujin Zhang; Monika Dzieciatkowska; Benjamin C Brown; Weiru Zhang; Tingting Xie; Osheiza Abdulmalik; Anren Song; Chao Tong; Hongbo Qi; Robert Roach; Rodney E Kellems; Angelo D'Alessandro; Yang Xia
Journal:  Cell Metab       Date:  2022-02-01       Impact factor: 31.373

4.  Diagnostic Challenge and Therapeutic Approaches in Human Sepsis Based on the Appearance of Endotoxemia and Beta-d-Glucanemia.

Authors:  Hiroshi Tamura; Yoshiyuki Adachi
Journal:  Int J Mol Sci       Date:  2021-11-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.